ARDX
Ardelyx Inc.
$5.42
-$0.13(-2.34%)
45
Overall
40
Value
50
Tech
--
Quality
Market Cap
$1.41B
Volume
3.61M
52W Range
$3.21 - $6.78
Target Price
$11.82
Company Overview
| Mkt Cap | $1.41B | Price | $5.42 |
| Volume | 3.61M | Change | -2.34% |
| P/E Ratio | -36.1 | Open | $5.52 |
| Revenue | $333.6M | Prev Close | $5.55 |
| Net Income | $-39.1M | 52W Range | $3.21 - $6.78 |
| Div Yield | N/A | Target | $11.82 |
| Overall | 45 | Value | 40 |
| Quality | -- | Technical | 50 |
No chart data available
About Ardelyx Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts’ Top Healthcare Picks: Harrow Health (HROW), Ardelyx (ARDX)
Christine Brown•13 days ago
Ardelyx’s Phase 3 Study on Tenapanor: A Potential Game-Changer for Pediatric IBS-C
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARDX | $5.42 | -2.3% | 3.61M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |